BD1.AX - BARD1 Life Sciences Limited

ASX - ASX Delayed price. Currency in AUD

BARD1 Life Sciences Limited

Unit 202, 39 Mends Street
Level 2
South Perth, WA 6151
61 8 9381 9550

IndustryDiagnostics & Research
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.Chief Exec. Officer389.4kN/AN/A
Dr. Irmgard Irminger-Finger B.Sc., M.Sc., PD, Ph.D.Founder, Exec. Director & Chief Scientific Officer150kN/AN/A
Mr. Peter Lynton Gunzburg B Comm, ASIAManaging Director75.28kN/A1952
Mr. Tony Di PietroCFO & Company Sec.N/AN/AN/A
Mr. Carl S. StubbingsChief Operating OfficerN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a screening test for the early detection of lung cancer in high-risk asymptomatic individuals; and BARD1 ovarian cancer test to detect ovarian cancer in high-risk women with a family history of breast/ovarian cancer or carrying BRCA1/2 mutations. The company has a collaboration with the Institute for Respiratory Health to evaluate a potential BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models. BARD1 Life Sciences Limited is based in South Perth, Australia.

Corporate governance

BARD1 Life Sciences Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.